Our Bureau
Mumbai
Pharma stocks have been heavily impacted by the 100% tariffs introduced by the President of the United States Donald Trump on branded and patented drugs being imported in to US. This Friday, on September 26th, the pharma stocks prices dropped and the biggest brunt of that was faced by Sun Pharma Ltd as it dropped to yearly low at Rs 1,547.27 at the opening bell. The stock had gained 1.5% over the last one month.
These tariffs will be imposed from the start of the next month i.e., 1st October. It was also reported that these tariffs will not be applicable to the companies who have their manufacturing plants in the United States or are currently building plants in the US, or have broken ground for building plants in the US.
Sun Pharma has key products like Illumya, Cequa, Odomozo, and Winlevi and the entire business amounts for around 19.3% of its overall sales. In financial year 2025, Sun Pharma’s specialty sales saw a massive hike of 17% from last year and reached $1.2 billion. On the other end global Illumya sales have seen a growth of 17% to now reach $681 million.
It is to be noted that the company has not disclosed the sales they had from the US plants. The management has earlier indicated that the current capacity is good enough in case they need to undertake onshore manufacturing, without adding new capacity
Aditya Khemka of InCred Asset Management has stated that he believes that the possibility of tariffs being imposed on Pharma generics cannot be ruled out. The US Commerce Department had also hinted that some Pharmaceuticals will be covered in a completely different sectors than others.
“Pharmaceuticals, such as prescription drugs, over-the-counter drugs, biologics, and specialty drugs, will not be covered under this investigation as those imports are being examined in a separate Section 232 investigation,” the US Commerce Department said.
